SPONSORED

ABOUT THIS EPISODE

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let’s Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let’s Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.
English
United States
SPONSORED

TRANSCRIPT

Disclaimer: The podcast and artwork embedded on this page are from PVI, PeerView Institute for Medical Education, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

EDIT

Thank you for helping to keep the podcast database up to date.
SPONSORED

RECOMMENDATIONS